Drug-eluting surgical articles with a plurality of geometric elements
Disclosed herein is a biomaterial for treating a condition. A biomaterial of the disclosure can be, for example, a surgical article. The biomaterial can comprise a plurality of geometric elements and a therapeutic agent. The biomaterial can comprise a first geometric element formed by a porous border that comprises a polymer and the therapeutic agent. The biomaterial can comprise a second geometric element formed by a non-porous border and a solid region, wherein the therapeutic agent may not diffuse into the second geometric element. Implantation of a biomaterial disclosed herein into a subject can treat, for example, cancer.
1. A biomaterial comprising a first plurality of geometric elements and a therapeutically-effective amount of a therapeutic agent, wherein:
a first geometric element of the first plurality of geometric elements is formed by a first porous border, wherein the first porous border comprises a polymer and the therapeutic agent;
a second geometric element of the first plurality of geometric elements is formed by a non-porous border and a first solid region comprising the polymer, wherein the therapeutic agent cannot diffuse into the second geometric element;
the first solid region is adjacent to and within the non-porous border; and
a portion of the first porous border is adjacent to a portion of the non-porous border.
2. The biomaterial of claim 1 , wherein the first geometric element comprises an empty space within the first porous border.
3. The biomaterial of claim 1 , wherein the first geometric element is formed by the first porous border and a second solid region comprising the polymer, wherein the second solid region is adjacent to and within the first porous border.
4. The biomaterial of claim 3 , wherein the second solid region has a degree of porosity that allows the therapeutic agent to diffuse into the second solid region from the first porous border.
5. The biomaterial of claim 3 , further comprising a third geometric element of the first plurality of geometric elements, wherein the third geometric element is formed by a second porous border comprising the polymer and the therapeutic agent, wherein a portion of the second porous border is adjacent to at least one of:
a portion of the first porous border; and
a portion of the non-porous border.
6. The biomaterial of claim 5 , wherein the third geometric element is formed by the second porous border and a third solid region comprising the polymer and the therapeutic agent, wherein the third solid region is adjacent to and within the second porous border.
7. The biomaterial of claim 5 , further comprising a fourth geometric element of the first plurality of geometric elements, wherein the fourth geometric element is formed by:
(i) a third porous border comprising the polymer and the therapeutic agent; and
(ii) a third solid region comprising the polymer;
wherein a portion of the third porous border is adjacent to at least one of:
a portion of the first porous border;
a portion of the second porous border; and
a portion of the non-porous border,
wherein the third solid region is adjacent to and within the third porous border.
8. The biomaterial of claim 1 , wherein the first plurality of geometric elements forms a first layer, and wherein the biomaterial further comprises a second layer, wherein the second layer comprises a second plurality of geometric elements, wherein the second layer is in contact with the first layer and is layered onto the first layer.
9. The biomaterial of claim 1 , wherein the therapeutic agent is an anti-cancer agent.
10. The biomaterial of claim 1 , wherein the therapeutic agent is an anti-inflammatory agent.
11. The biomaterial of claim 1 , wherein the therapeutic agent is an antibiotic.
12. The biomaterial of claim 1 , wherein the therapeutic agent is an analgesic.
13. The biomaterial of claim 1 , wherein the therapeutic agent is 5-fluorouracil.
14. The biomaterial of claim 1 , wherein the polymer is polycaprolactone (PCL).
15. The biomaterial of claim 1 , wherein the polymer is poly lactic acid (PLA).
16. The biomaterial of claim 1 , wherein the polymer is poly L-lactide-glycolic acid (PLGA).
17. The biomaterial of claim 1 , wherein the polymer is polyethylene glycol diacrylate (PEGDA).
18. The biomaterial of claim 1 , wherein the first porous border further comprises a porogen.
19. The biomaterial of claim 18 , wherein the porogen is a bioactive glass.
20. The biomaterial of claim 1 , wherein the biomaterial is biodegradable.
21. The biomaterial of claim 1 , wherein the therapeutic agent is gemcitabine.